Lantheus (NASDAQ:LNTH) Price Target Raised to $78.00

Lantheus (NASDAQ:LNTH) had its price objective hoisted by Citizens Jmp from $73.00 to $78.00 in a report released on Tuesday morning,Benzinga reports. The firm currently has a market outperform rating on the medical equipment provider’s stock.

Several other analysts also recently issued reports on the company. Citigroup reiterated an “outperform” rating on shares of Lantheus in a report on Tuesday. Mizuho increased their target price on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Truist Financial boosted their price target on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $78.83.

Lantheus Price Performance

LNTH stock opened at $75.43 on Tuesday. The company has a market cap of $5.00 billion, a PE ratio of 31.69 and a beta of -0.08. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. The stock has a 50-day moving average price of $67.97 and a two-hundred day moving average price of $60.01. Lantheus has a 12-month low of $47.25 and a 12-month high of $111.29.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.50. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The business had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. During the same period in the previous year, the company posted $1.59 EPS. The company’s revenue was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, research analysts predict that Lantheus will post 6.01 EPS for the current year.

Hedge Funds Weigh In On Lantheus

Several institutional investors and hedge funds have recently made changes to their positions in LNTH. M&T Bank Corp acquired a new stake in Lantheus in the fourth quarter valued at $370,950,000. Farallon Capital Management LLC grew its position in shares of Lantheus by 56.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after acquiring an additional 1,950,252 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Lantheus in the 3rd quarter valued at approximately $65,654,000. Norges Bank acquired a new stake in shares of Lantheus during the 4th quarter valued at approximately $76,197,000. Finally, Polaris Capital Management LLC acquired a new position in Lantheus in the third quarter worth $32,687,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Key Lantheus News

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 beat — Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected, with improved margins and ROE, supporting near‑term earnings power. MarketBeat: Q4 results
• Positive Sentiment: Analyst upgrade — William Blair upgraded LNTH to “Outperform,” a vote of confidence that can support buying interest. Street Insider: William Blair upgrade
• Positive Sentiment: Price target increase — Citizens Jmp raised its price target to $78, which can provide a modest valuation floor for the shares. American Banking News: PT raise
• Neutral Sentiment: Earnings call / disclosure materials posted — Full earnings call transcript, slide deck and press release are available for investors to dig into segment details and management commentary. Seeking Alpha: Earnings call transcript
• Negative Sentiment: Cautious FY‑2026 guidance — Management set EPS guidance of $5.00–$5.25 (consensus ~5.16) and revenue guidance $1.4B–$1.5B (consensus ~$1.5B). The midpoint and lower end of the revenue range are slightly light versus Street expectations, creating near‑term uncertainty on growth trajectory. GlobeNewswire: Q4 results & guidance
• Negative Sentiment: Intraday selling on mixed setup — despite the beat and upgrades, investors pulled back on the guidance and booked profits after a big run from the stock in the prior year. WTOP: Earnings snapshot

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.